pyrimidinones and Carcinoma--Papillary

A multi-institutional, randomized phase II trial of continuous dosing of dabrafenib with or without trametinib is ongoing in metastatic thyroid cancer. Preclinical evidence and emerging clinical experience in other cancers support evaluating intermittent dosing of these two agents to achieve more durable response, while being better tolerated and more cost effective.. Two consecutive patients with symptomatic, metastatic radioactive iodine-resistant BRAF. Both patients showed rapid clinical improvement upon starting the regimen. They also noted improved tolerance of treatment upon transitioning to the intermittent dosing schedule. They continue to show evidence of antitumor activity 27 and 18 months respectively from the start of treatment and 15 and 13 months respectively from the start of the first break using intermittent dosing.. Achieving durable palliation in these consecutive patients supports evaluating the intermittent dosing schedule of dabrafenib and trametinib in BRAF

Topics: Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Drug Administration Schedule; Drug Monitoring; Female; Humans; Imidazoles; Middle Aged; Mutation; Oximes; Palliative Care; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome